<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04055883</url>
  </required_header>
  <id_info>
    <org_study_id>DA1229_CAVD_II</org_study_id>
    <nct_id>NCT04055883</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD</brief_title>
  <acronym>DIP-CAVD</acronym>
  <official_title>A Multicenter, Double-blind, Placebo-controlled, Stratified-randomized, Parallel, Therapeutic Exploratory Clinical Study to Evaluate the Efficacy and Safety of DA-1229 in Patients With Calcific Aortic Valve Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of DA-1229 in patients with calcific aortic&#xD;
      valve disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>aortic valve calcium volume change</measure>
    <time_frame>96 weeks</time_frame>
    <description>aortic valve calcium volume change compared to baseline(mm^3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>aortic valve calcium volume change</measure>
    <time_frame>48 weeks</time_frame>
    <description>aortic valve calcium volume change compared to baseline(mm^3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aortic valve calcium score change</measure>
    <time_frame>48 weeks, 96 weeks</time_frame>
    <description>aortic valve calcium score change compared to baseline(AU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>aortic valve calcium volume change percent</measure>
    <time_frame>48 weeks, 96 weeks</time_frame>
    <description>aortic valve calcium volume change percent compared to baseline(%)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Calcific Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>DA-1229 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of DA-1229 5mg tablet once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-1229 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of DA-1229 10mg tablet once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-1229 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of DA-1229 Placebo tablet once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-1229</intervention_name>
    <description>All participants are administered one tablet per day for 96 weeks</description>
    <arm_group_label>DA-1229 10mg</arm_group_label>
    <arm_group_label>DA-1229 5mg</arm_group_label>
    <arm_group_label>DA-1229 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male and female subjects of ages in the range over 19&#xD;
&#xD;
          -  The subjects whose echocardiography or heart CT result meets the criterion in the&#xD;
             screening period or 4 weeks before screening visit&#xD;
&#xD;
               -  Criterion : 2.0m/s ≤ peak aortic-jet velocity &lt; 4.0m/s or aortic valve calcium&#xD;
                  score ≥300AU&#xD;
&#xD;
          -  The subjects completely understood the clinical trial through detailed explanation&#xD;
             presented, determined to participate in the clinical trial spontaneously, and agreed&#xD;
             to observe precautions suggested thereby through written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The cause of CAVD is niether degenerative nor bicuspid aortic valve&#xD;
&#xD;
          -  The subjects who have other aortic valve disease as other clinically significant&#xD;
             aortic insufficiency or mitral disease&#xD;
&#xD;
          -  The subjects who had an aortic valve operation or are expected to need aortic valve&#xD;
             operation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Bundang-gu</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <state>Donggu</state>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyeongpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Jung-gu</state>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <state>Jung-gu</state>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Yangsan</city>
        <state>Mulgeum-eup</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-gu</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>August 22, 2021</last_update_submitted>
  <last_update_submitted_qc>August 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Disease</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

